| Human |
Plasma from healthy and critically ill patientsdiluted to 4 mg/ml |
10 mM DNPH (in 6 M guanidine HCl, 0.5 M potassium phosphate buffer, pH 2.5) |
Biotinylated anti-DNP (Molecular Probes) |
MaxiSorp (Nunc) |
0.06–0.75 nmol/mg |
[20,62] |
|
|
Ratio sample/DNPH (1:4) |
Streptavidin-biotinylated-HRP (Amersham) |
|
|
|
|
|
45 min at RT |
|
|
|
|
| Human |
Plasma from sepsis patients vs controls |
n.a. |
Biotin-conjugated polyclonal anti-DNP IgG |
n.a. |
0.32–0.45 nmol/mg |
[63] |
|
Dilution n.a. |
|
Streptavidin-conjugated HRP |
|
|
|
| Human |
Citrate-plasma from schizophrenia patients and healthy volunteers |
n.a. |
n.a. |
n.a. |
0.178–0.482 nmol/mg |
[64] |
|
Dilution n.a |
|
|
|
|
|
| Human |
Heparin and EDTA plasma and urine |
n.a. |
n.a. |
n.a. |
Significantly higher concentration in blood of subway workers and bus drivers than in office workers (17 and 18 vs. 15 nmol/ml) |
[65] |
|
Dilution n.a. |
|
|
|
|
|
| Human |
Plasma from 71 hepatocellular carcinoma patients and 694 controls |
n.a. |
n.a. |
n.a. |
0.11–1.41 nmol/mg |
[66] |
|
Dilution n.a. |
|
|
|
|
|
| Human |
Plasma of chronic obstructive pulmonary disease (COPD) patients |
n.a. |
Polyclonal rabbit anti-DNP (Molecular Probes) |
MaxiSorp (Nunc) |
17.9±2.9 nmol/mg |
[67] |
|
4 mg/ml |
|
HRP-conjugate (Amersham) |
|
|
|
| Human |
Plasma from participants of the New York Early Lung Cancer Action Project |
n.a. |
Polyclonal rabbit anti-DNP (Molecular Probes) |
n.a. |
~17 nmol/ml |
[68] |
|
4 mg/ml |
|
HRP-conjugate (Amersham) |
|
|
|
| Human |
Plasma |
10 mM DNPH (in 6 M guanidine–HCl, 0.5 M potassium phosphate, pH 2.5) |
Biotinylated anti-DNP (Molecular Probes) |
ELISA (Corning Costar) |
~11–15.3 nmol/mg |
[69] |
|
4 mg/ml |
Ratio and conditions n.a. |
Streptavidin–biotin HRP (Amersham) |
|
|
|
| Human |
Serum from middle-aged obese subjects |
Concentration and conditions n.a. |
n.a. |
n.a. |
0.12 arb. u. |
[70] |
|
4 mg/ml |
Ratio (1:4) |
|
|
|
|
| Human |
Heparin plasma |
0.05 mM DNPH (in H3PO4, pH 6.2) |
Anti-DNP (Sigma) |
n.a. |
Method for measuring protein carbonyl in samples with low amounts of protein |
[25] |
|
5 µg/ml |
45 min at RT in the dark |
Anti-rabbit HRP-linked IgG (H&L, Upstate Cell Signaling) |
|
|
|
|
|
NOTE: derivatization after samples have adsorbed to the plate! |
|
|
|
|
| Human |
Plasma and LDL |
n.a. |
Anti-DNP (Dako) |
n.a. |
Modification of method |
[71] |
|
Dilution n.a. |
|
Goat anti-rabbit IgG peroxidase conjugate (Sigma) |
|
|
|
| Human |
Plasma |
n.a. |
n.a. |
n.a. |
0.1–0 5 nmol carbonyl groups fibrinogen/mg of plasma proteins |
[72] |
|
Dilution n.a. |
|
|
|
|
|
| Human |
Plasma from women with preeclampsia and controls |
45 min at RT |
Rabbit anti-DNP-KLH (Invitrogen) |
n.a. |
Significantly higher concentration in cases than in controls |
[73] |
|
Dilution n.a. |
|
HRP-conjugated porcine anti-rabbit IgG (Dako A/S) |
|
|
|
| Human |
Plasma |
n.a. |
Biotinylated anti-DNP (Molecular Probes) |
n.a. |
|
[74] |
|
4 mg/ml |
|
Streptavidin-biotinylated HRP-conjugate (Amersham) |
|
|
|
| Human |
K562 cell lysates (human chronic myelogenous leukemia) |
n.a. |
Rabbit anti-DNP IgG antiserum (Sigma) |
n.a. |
Relation to control |
[75] |
|
1 mg/ml in lysis buffer with 1 mM BHT |
|
Monoclonal anti-rabbit peroxidase-conjugated IgG (Sigma) |
|
|
|
| Human |
Parenchymal lung tissue of current smokers with chronic obstructive pulmonary disease |
n.a. |
Plate was pre-incubated with mouse anti-HSA before addition of samples |
n.a. |
0.5–5 carbonyl residues/HSA molecule |
[76] |
|
Dilution n.a. |
|
rabbit anti-DNP |
|
|
|
|
|
|
Anti-rabbit HRP-conjugate |
|
|
|
| Human |
MRC-5-fibroblast cell lysates (fetal lung) |
n.a. |
Anti-DNP rabbit-IgG-antiserum (Sigma) |
n.a. |
~1.5–3.2 nmol/mg |
[77] |
|
4 mg/ml |
|
Monoclonal anti-rabbit-IgG-peroxidase conjugated (Sigma) |
|
|
|
| Mouse |
Brain, liver, heart and spleen homogenates from 6-week-old male DDY mice |
10 mM DNPH (in 2 M HCl) |
n.a. |
n.a. |
Relation to control |
[78] |
|
1 mg/ml |
For 1 h at RT |
|
|
|
|
|
|
Ratio n.a. |
|
|
|
|
| Mouse |
Heart tissue homogenate of SAMP8 mice |
n.a. |
Rabbit anti-DNP IgG-antiserum (Sigma Aldrich) |
n.a. |
664±37 nmol/g (high-polyphenol diet) and 958±70 (low-polyphenol diet) nmol/g |
[79] |
|
Dilution n.a. |
|
Monoclonal anti-rabbit IgG peroxidase conjugate (Sigma Aldrich) |
|
|
|
| Mouse |
Mesenchymal stem cells derived from adipose tissue of C57/Black6 mice |
n.a. |
n.a. |
n.a. |
4–32 Carbonyls/mg protein |
[80] |
|
Dilution n.a. |
|
|
|
|
|
| Mouse |
Brain homogenate from ApoD-knockout mice |
n.a. |
Biotinylated anti-DNP (Molecular Probes) |
n.a. |
Relation to control |
[81] |
|
Dilution n.a. |
|
Streptavidin-biotinylated HRP (Amersham) |
|
|
|
| Mouse |
Isolated mitochondria from livers of Bcs1lG/G mice |
Concentration and ratio n.a. |
Anti-DNP (Invitrogen) |
n.a. |
1.09±0.36 relative amount |
[82] |
|
Dilution n.a. |
45 min at RT |
Swine anti-rabbit IgG-HRP (Dako A/S) |
|
|
|
| Mouse |
Retinal pigmented epithelial cell lysates |
10 mM DNPH (in 6 M guanidine–HCl, 0.5 M potassium phosphate, pH 2.5) |
Polyclonal rabbit anti-DNP (Molecular Probes) |
MaxiSorp (Nunc) |
0.6–1.2 nmol |
[83] |
|
4 mg/ml |
Ratio (1:4) |
HRP-conjugate (Amersham) |
|
|
|
|
|
45 min at RT |
|
|
|
|
| Mouse |
RAW264.7 murine macrophage-like cells |
Kit from Cell Biolabs |
Kit from Cell Biolabs |
Kit from Cell Biolabs |
Results not significant |
[84] |
|
Dilution n.a. |
|
|
|
|
|
| Mouse |
HT22 cell lysates4 mg/ml in lysis buffer with 1 mM BHT |
n.a. |
Rabbit anti-DNP IgG antiserum (Sigma) |
n.a. |
6.5–9.0 pmol/mg |
[85] |
|
|
|
Monoclonal peroxidase-conjugated anti-rabbit IgG (Sigma) |
|
|
|
| Rat |
Ileal mucosa of salmonella infected rats |
n.a. |
Biotinylated anti-DNP (Molecular Probes), streptavidin-biotinylated HRP (Amersham) |
MaxiSorp (Nunc) |
0.1–0.2 nmol/mg |
[86] |
|
4 mg/ml |
|
|
|
|
|
| n.a. |
Ferritin |
(10 mM in 6 M guanidine HCl, 0.5 M potassium phosphate, pH 2.5) |
Biotinylated anti-DNP |
MaxiSorp(Nunc) |
0.55–1.0 nmol/mg |
[87] |
|
Dilution n.a. |
Ratio (1:3) |
Anti-rabbit-IgG-peroxidase (γ-chain specific) |
|
|
|
|
|
45 min at RT |
|
|
|
|
